Okamura et al. (2025) reported the successful treatment of a patient with BP and PV overlap with bimekizumab, a humanized monoclonal antibody that inhibits both IL-17A and IL-17F [66]. This evidence concerns the gene IL17A and acquired polycythemia vera.